logo-loader

Regeneus brings stem cell technology to Proactive's CEO Sessions

Published: 22:00 31 May 2017 EDT

regeneus_john-in-japan-757
John Martin, CEO, Regeneus, meeting business leaders in Japan recently

Regeneus (ASX:RGS) flagship asset is a patented off-the-shelf stem cell technology for the treatment of knee osteoarthritis and other inflammatory conditions.

The company has entered licensing agreements in Japan.

Japan, with its rapidly ageing population, is committing itself to world-leading reform and investment in the field of regenerative medicine.


Find out more from John Martin at Proactive's CEO Sessions.


Click below to register by email

- Sydney: Wednesday 14th June.
- Melbourne: Thursday 15th June.
- Email Pauline here.
- Call office on (02) 9280 0700.

Presenter list

- Regeneus (ASX:RGS): MD John Martin
- Tlou Energy (ASX:TOU): MD & CEO Tony Gilby
- AuKing Mining (ASX:AKN): MD Paul Williams
- XTEK (ASX:XTE): MD Philippe Odouard
- Pioneer Resources (ASX:PIO): MD David Crook

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 34 minutes ago